Company profile
Repligen Corporation
NASDAQ: RGEN · Healthcare · Medical - Instruments & Supplies
#182 of 1,418 Healthcare companies by revenue62nd-percentile growth
EA Score
82B+FH 83DQ 91GM 53SS 94
v0.1 · 65/100 weight · provisional
↑ listing tenure, market scale · ↓ 3-yr revenue growth, growth stability
Methodology →Revenue TTM
$763.3M
Rev growth YoY (TTM)
+17.4%
Net income (FY)
$48.9M
Employees
2,000
as of 2026-08-06
Market cap
$9.0B
as of 2026-08-06
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$738.3M$738.3M2025
Net income$48.9M$48.9M2025
Operating income$55.2M$55.2M2025
Total assets$2.9B$2.9B2025
Liabilities$843.6M$843.6M2025
Equity$2.1B$2.1B2025
Revenue trend
FY2020 – FY2025 · USD
FY20
FY20
FY20
FY21
FY22
FY23
FY24
FY25
Revenue by segment
Filed disclosures · FY2025
By product
Product50%
Filtration Products27%
Chromatography Products10%
Proteins Products7%
Process Analytics Products6%
Other products0%
By geography
Not disclosed.
The read
What is Repligen Corporation’s revenue?
Repligen Corporation booked $738.3M in FY2025 revenue, growing 16% year over year — faster than most Healthcare companies we track, at a 6.6% net margin.
Peers · Healthcare
Corcept Therapeutics Incorporated84B+iRhythm Technologies, Inc.75B+Emergent BioSolutions Inc.69BNeoGenomics, Inc.72BPacira BioSciences, Inc.78B+Amphastar Pharmaceuticals, Inc.77B+Neighbors
Middlesex →Key facts
CEOOlivier Loeillot
SectorHealthcare
IndustryMedical - Instruments & Supplies
HeadquartersWaltham, MA
ExchangeNASDAQ: RGEN
Employees2,000
IPO date1986-04-29
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.